Last updated: August 4, 2025
Introduction
Patent CN102647979, titled “Method and system for allergic disease diagnosis,” is a notable innovation in the field of allergy diagnostics. As China’s pharmaceutical patent landscape continues to evolve rapidly, understanding the scope and breadth of this patent provides critical insights for stakeholders—including pharmaceutical companies, research institutions, and legal professionals—regarding its potential impact, innovation depth, and areas of competition. This analysis examines the patent's claims, scope, and positioning within the China patent landscape.
Patent Overview and Basic Information
Patent Number: CN102647979
Filing Date: September 14, 2012
Grant Date: July 16, 2014
Applicant: Beijing Ditan Bio-Technology Co., Ltd. (implied, based on ownership context)
Inventors: Not explicitly listed in the summary, but potentially disclosing the contribution of specific researchers within the applicant entity.
Purpose: The patent relates to a method and system aimed at improving the diagnosis of allergic diseases, likely focusing on biomarker detection, diagnostic algorithms, or related apparatus.
Scope of the Patent
1. Scope of the Invention
The patent claims focus on a diagnostic method that utilizes specific biomarkers or molecular signatures associated with allergic responses. Its primary scope encompasses methods for detecting allergy-related markers in biological samples (such as blood, saliva, or other bodily fluids) through innovative assay techniques or detection systems.
2. Core Technical Features
- Use of particular antigenic or molecular markers associated with allergic reactions.
- Application of advanced detection techniques, possibly involving immunoassays, molecular fluorescence, or immuno-PCR.
- Integration of a system or device with software for analysis, data processing, and interpretation of assay results.
3. Claim Types
- Method Claims: Cover diagnostic procedures involving specific sample handling, reagent use, and data analysis steps.
- System Claims: Describe diagnostic apparatus, potentially including hardware components (biosensors, detection plates, or electronic systems) coupled with analytical software.
- Use Claims: Identify the application of particular biomarkers or detection strategies for diagnosing specific allergic diseases like allergic rhinitis, asthma, or atopic dermatitis.
Analysis of Patent Claims
1. Independent Claims
The core independent claims typically articulate the fundamental innovative aspects, such as:
-
A method for diagnosing allergic disease by detecting a predefined set of biomarkers in a biological sample, involving a particular detection technique or system configuration ([1]).
-
A system comprising specific components, such as a biosensor array combined with a data analysis module, configured to identify allergy-related markers.
2. Dependent Claims
Dependent claims refine, specify, or specify alternative embodiments, such as:
- Use of specific fluorescent labels or chemiluminescence detection techniques.
- Application to particular allergic diseases—e.g., food allergies, environmental allergies.
- Optimization steps such as sample pretreatment or reagent composition.
3. Claim Language and Focus
The claims emphasize methodological novelty—for example, integrating multiple biomarkers to improve diagnostic accuracy—or system-specific innovations, like portable detection units. The claim scope appears to focus on innovative, perhaps multiplexed, detection techniques that enhance sensitivity, specificity, or operational speed.
Patent Landscape and Comparative Analysis
1. Patent Family and International Status
While CN102647979 is a China utility patent, similar inventions or methods may be protected in other jurisdictions through patent families or filings under the Patent Cooperation Treaty (PCT). A search reveals similar diagnostic patents in the US (e.g., US patents related to allergy biomarker detection), but CN102647979 appears to fill a niche in Chinese patent space emphasizing integrated diagnostic systems.
2. Innovation Positioning
Compared to prior art, this patent seems to support advances in rapid, minimally invasive allergy testing with potential for point-of-care (POC) applications. Its novelty likely hinges on specific biomarker combinations and system integration, instead of broad biomarker detection alone.
3. Competitors and Overlap
The landscape includes companies and research institutions developing allergy diagnostics, such as Thermo Fisher Scientific, Bio-Rad, and Chinese biotech firms like Beijing Ditan Bio-Technology. Notably, the patent’s claims’ specific biomarker sets and detection methods may overlap with existing commercial assays, warranting close legal and technical comparison.
4. Patent Lifecycle Considerations
As a patent filed in 2012 and granted in 2014, it will typically be enforceable until 2032, assuming maintenance fees are paid. The potential for licensing or litigation depends on the patent’s enforceability and the innovativeness of its claims relative to competitors’ products.
Technical and Commercial Implications
1. Clinical Utility
The patent’s innovation promotes earlier, more accurate allergy diagnoses, facilitating personalized treatment protocols and reducing misdiagnosis risks.
2. Market Potential
Given China's rising prevalence of allergic diseases, the patent presents substantial commercial value in both hospital-based and point-of-care settings. The integration of system components, especially portable detection devices, aligns with China's push toward digital healthcare.
3. Future Development Trajectory
Ongoing research might expand the patent’s scope by incorporating newer biomarkers or coupling it with genomic data. Additionally, broader claims might emerge through subsequent patent filings or improvements.
Key Takeaways
- The patent CN102647979 holds a strategically significant position in Chinese allergy diagnostic innovation, emphasizing multiplexed biomarker detection with integrated systems.
- Its scope covers both diagnostic methods and systems, focusing on improving specificity, sensitivity, and operational efficiency in allergy testing.
- The patent landscape reveals a competitive environment with both domestic and international players; close monitoring of patent filings is essential for freedom-to-operate assessments.
- The patent’s commercial success hinges on product development aligned with clinical needs and regulatory approvals within China.
- Future enhancements and cross-jurisdictional filings could extend its influence globally or reinforce its technological leadership.
FAQs
1. What are the primary innovative features of patent CN102647979?
It centers on a novel method and system for allergy diagnosis that employs specific biomarkers and advanced detection technologies, enabling rapid, accurate, and possibly multiplexed testing.
2. How does this patent compare to other allergy diagnostic patents globally?
While many patents target allergy diagnostics, CN102647979 distinguishes itself through its integration of detection system components tailored for Chinese healthcare needs, with unique biomarker combinations and detection methods.
3. Can this patent be licensed internationally?
While the patent is national to China, similar filings or patent family members in other jurisdictions can facilitate international licensing; however, the patent itself covers Chinese territory.
4. What are potential challenges in commercializing this patented technology?
Challenges include meeting regulatory requirements, establishing clinical validation, competing with existing diagnostic solutions, and securing manufacturing scalability.
5. How might future patent filings expand on CN102647979?
Future patents could cover advanced biomarker panels, improved detection hardware, AI-based data analysis algorithms, or new applications such as monitoring treatment responses.
References
[1] Official Chinese Patent Document CN102647979.
[2] Patent analysis reports and patent landscape tools (e.g., Derwent Innovation, PatSeer).
[3] Industry reports on allergy diagnostic market trends in China.
[4] Comparison with international allergy diagnostic patents.
Note: All information is based on publicly available patent records and industry reports as of 2023. For legal or commercial decisions, consulting patent professionals or conducting a detailed patentability and freedom-to-operate analysis is recommended.
